Genetic predisposition in chemotherapy ‐induced cardiomyopathy in a 65‐year‐old female with metastatic breast cancer
We present a case of a 65-year-old woman with breast cancer who developed recurrent CTRCD following low-dose chemotherapy, despite lacking conventional cardiovascular risk factors. Her medical history included anthracycline-associated cardiomyopathy, and her condition deteriorated significantly after treatment with HER2-targeted therapies. Through the use of multimodal imaging, we detected severe left ventricular systolic dysfunction. Further investigation with genetic testing revealed a likely pathogenic variant in theTNNT2 gene, suggesting a genetic predisposition to CTRCD. This case implies the potential role of genetic screening in identifying patients at risk for CTRCD and advocates for personalized chemotherapy and cardioprotective strategies.
Source: ESC Heart Failure - Category: Cardiology Authors: So ‐Young Lee,
Hoon Seok Kim,
Mi‐Hyang Jung,
Suyon Chang,
Myungshin Kim,
Jong‐Chan Youn,
Woo‐Baek Chung,
Hae Ok Jung Tags: Case Report Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiomyopathy | Cardiovascular | Chemotherapy | Genetics | Heart | Heart Failure | HER2 | Study